Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
- 1 January 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (1) , 183-193
Abstract
Purpose: To evaluate whether, in patients with non–small cell lung carcinoma (NSCLC), tumor uptake of [11C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of tracer uptake corresponds with the presence of activating tumor EGF receptor (EGFR) mutations.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracerBritish Journal of Cancer, 2011
- Quantitative Parametric Perfusion Images Using 15O-Labeled Water and a Clinical PET/CT Scanner: Test–Retest Variability in Lung CancerJournal of Nuclear Medicine, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patientsBritish Journal of Cancer, 2008
- Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to GefitinibCancer Research, 2007
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLOS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Estimating the Dimension of a ModelThe Annals of Statistics, 1978